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Abstract: Solid self-emulsifying drug delivery system (SSEDDS), which incorporates liquid 
SEDDS into a solid dosage form, has been recently introduced to improve the oral bioavail-
ability of poorly water-soluble drugs. However, supersaturated drug generated by SSEDDS is 
thermodynamically unstable and tends to precipitate rapidly prior to absorption, resulting in 
compromised bioavailability. The aim of this study was to construct a novel supersaturated 
SSEDDS (super-SSEDDS) by combining SSEDDS with appropriate precipitation inhibitor. 
Fenofibrate (FNB), a sparingly soluble drug, was selected as a model drug in this study. 
An optimized SSEDDS was prepared by solvent evaporation by using mesoporous silica Santa 
Barbara Amorphous-15 as the inert carrier. Supersaturation assay was conducted to evaluate the 
precipitation inhibition capacity of different polymers, and the results showed that Soluplus® 
could retard the FNB precipitation more effectively and sustain a higher apparent concentra-
tion for ~120 min. This effect was also clearly observed in the dissolution profiles of FNB 
from SSEDDS under supersaturated condition. The study of the mechanism suggested that the 
inhibition effect might be achieved both thermodynamically and kinetically. The area under 
the concentration–time curve of the super-SSEDDS was 1.4-fold greater than that of SSEDDS 
in the absence of Soluplus, based on an in vivo pharmacokinetic study conducted in beagle 
dogs. This study has demonstrated that the approach of combining SSEDDS with Soluplus 
as a supersaturation stabilizer constitutes a potential tool to improve the absorption of poorly 
water-soluble drugs.
Keywords: Soluplus, supersaturation, fenofibrate, mesoporous silica, poorly water-
soluble drugs
Introduction
In drug discovery, almost 70% of new drug candidates exhibit low aqueous solubility 
which ultimately results in poor absorption.1,2 A number of alternative techniques 
including cyclodextrin complexation,3 particle size reduction,4 solid dispersions,5 and 
lipid-based formulations6 have been developed to overcome this problem.
Among all the formulations, lipid-based formulations, especially self-emulsifying 
drug delivery systems (SEDDS) have received much attention.7 Recently, solid SEDDS 
(SSEDDS), prepared by incorporating the conventional liquid SEDDS preconcentrate 
into powder or particles, has been introduced to enhance the oral bioavailability of 
sparingly soluble drugs. It combines the advantages of liquid SEDDS (improved 
solubility and bioavailability) with those of solid dosage forms (storage stability and 
patient compliance).8,9 SSEDDS are supposed to maintain the self-emulsifying ability 
and capable of forming fine oil-in-water emulsions under gentle agitation provided by 
correspondence: Xin Pan; chuanbin Wu
school of Pharmaceutical sciences, sun 
Yat-sen University, 132 east circle at 
University Town, guangzhou 510006, 
china
Tel/fax +86 203 994 3427;  
+86 203 994 3120
email panxin2@mail.sysu.edu.cn; 
wuchuanb@mail.sysu.edu.cn 
Journal name: International Journal of Nanomedicine
Article Designation: Original Research
Year: 2017
Volume: 12
Running head verso: Quan et al
Running head recto: Supersaturable solid self-microemulsifying drug delivery system
DOI: http://dx.doi.org/10.2147/IJN.S149717
International Journal of Nanomedicine 2017:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
8802
Quan et al
the gastrointestinal (GI) motion.10 The drug presented in a dis-
solved form with a huge interfacial area for absorption provided 
by emulsion droplets results in an enhanced bioavailability.11,12 
In our previous study, solid self-emulsifying matrix combined 
with mesoporous silica was successfully prepared. When 
introduced to aqueous media under gentle agitation, the solid 
matrix exhibited excellent self-emulsifying properties of 
forming a uniform microemulsion.13
Nevertheless, the lipid-based formulation is limited by 
loss of solubilization capacity due to the digestion in GI tract. 
A supersaturated solution exceeding the equilibrium solu-
bility will be generated after administration. Theoretically, 
drugs at high concentration have an increased driving force 
for flux across the GI membrane, and enhanced absorption 
could be achieved with sufficient time period.14 However, 
supersaturated drug with higher chemical potential tends to 
precipitate rapidly into an energetically favorable crystalline 
form prior to the absorption, resulting in compromised bio-
availability.15 Therefore, ideal formulations should be able to 
maintain the supersaturated state for appropriate time period 
to allow better absorption.
A variety of pharmaceutical polymers have been 
widely explored to generate and maintain a supersaturated 
state of drugs for an extended period.16 These polymers 
have been confirmed to kinetically or thermodynamically 
inhibit the precipitation by retardation in drug nucleation 
and crystal growth or changing the properties of aqueous 
medium.17 Studies of several poorly water-soluble drugs, 
such as silybin,18 celecoxib,19 AMG 517,20 and halofantrine 
hydrochloride,21 clearly demonstrated that the SEDDS formu-
lations with polymeric precipitation inhibitors can result in 
better oral bioavailability when compared to the conventional 
SEDDS systems.
Soluplus (polyvinyl caprolactam–polyvinyl acetate–
polyethylene glycol graft copolymer) is a graft amphiphilic 
polymer introduced by Badische Anilin-und-Soda-Fabrik 
(BASF) to produce solid dispersions by hot-melt extrusion 
method.22 It shows excellent solubilization properties for 
poorly water-soluble drugs and subsequently increases the dis-
solution and oral absorption.23 In this regard, Soluplus could 
be a promising supersaturation stabilizer for SSEDDS. There-
fore, the aim of this study was to construct a supersaturated 
SSEDDS (super-SSEDDS) to improve the oral absorption of 
fenofibrate (FNB). Based on our previous report,13 SEDDS 
composed of ethyl oleate (EO) as oil, Cremophor RH40 as 
surfactant, and Transcutol® HP as cosurfactant was selected to 
solubilize FNB. Mesoporous silica was used as the solid res-
ervoir due to its unique properties including huge surface area 
and well-ordered porous interior. Herein, a super-SSEDDS 
system of FNB was formulated by screening various kinds 
of hydrophilic polymers and amphiphilic copolymers includ-
ing Soluplus as a precipitation inhibitor. The mechanism of 
precipitation inhibition was thermodynamically and kineti-
cally investigated. In vitro dissolution profile under non-sink 
condition was applied to characterize the performance of the 
super-SSEDDS. The in vivo oral bioavailability study was 
also performed in beagle dogs to determine the advantage of 
super-SSEDDS in oral absorption enhancement of FNB.
Materials and methods
Materials
FNB was obtained from Kaifeng Pharmaceutical Factory 
(Henan, China). Indomethacin was used as the internal stan-
dard and purchased from Wuhan DKY Technology Co., Ltd 
(Wuhan, China). Transcutol HP was provided by Gattefosse 
(Saint-Priest Cedex, France). Cremophor RH40, polyvi-
nylpyrrolidone Kollidon 30 (PVP K30), polyvinylpyrrolidone 
Kollidon 90 (PVP K90), vinylprrolidone–vinylacetate copoly-
mer Kollidon VA64 (PVP VA64), and Soluplus were kindly 
donated by BASF (Ludwigshafen, Germany). Hydroxypro-
pyl methyl cellulose E3 (HPMC E3), HPMC E5, and HPMC 
E15 were supplied by Dow Chemical Company (Midland, TX, 
USA). EO was purchased from Sinopharm Chemical Reagent 
Co., Ltd (Shanghai, China). All other chemicals and solvents 
were of reagent grade and used without further purification.
Preparation of sseDDs matrix
The solid self-emulsifying formulation was prepared accord-
ing to our previous report. Briefly, the formulation amount 
of FNB (15% w/w) was dissolved in the optimized liquid 
SEDDS consisting of 30% EO, 30% Cremophor RH40, and 
40% Transcutol HP. The resulting mixture was vortexed until 
a clear solution was obtained. Subsequently, liquid SEDDS 
was dissolved in 10 mL of ethanol followed by addition of 
solid carrier, and then the mixture was continuously stirred 
at room temperature for 24 h to reach the absorption equilib-
rium. Finally, ethanol was evaporated at 45°C for 48 h and 
the remaining matrix powder was collected. Santa Barbara 
Amorphous-15 (SBA-15) mesoporous silica and Aerosil® 
200 were used as solid absorbents. The fixed amounts of 
absorbent to liquid SEDDS in ratios of 1:1, 1:2, 1:3, and 1:4 
(wt %) were adopted to evaluate the absorption capacity.
characterization of sseDDs matrix
The outer macroscopic structures of FNB powder and 
SSEDDS matrix were observed by scanning electron 
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microscopy (JSM-6330F; JEOL, Tokyo, Japan). The physical 
state of samples was examined by X-ray diffraction (Bruker/
D2 PHASER; Bruker, Karlsruhe, Germany) using Cu Kα 
radiation with the scanning rate of 5°/min in the range of 
5°–40°. The nitrogen absorption–desorption isotherms were 
obtained at -196°C by using a surface area and pore size ana-
lyzer (ASAP 2020C; Micromeritics, Atlanta, GA, USA), and 
the surface area, pore volume, and pore diameter distribution 
of samples were calculated according to the isotherms.
reconstitution test
The SSEDDS system should be able to redisperse quickly 
into emulsion when introduced to aqueous media under mild 
agitation. Samples of SSEDDS (0.4 g) and preconcentrated 
liquid SEDDS (0.3 g) were dispersed in 200 mL water with 
magnetic stirring (50 rpm). In order to minimize the interfer-
ence of insoluble mesoporous silica particles, the resulting 
mixture was allowed to stand at ambient temperature for 12 h. 
Then the appearance of the supernatant was observed in the 
presence of a red laser light passageway. The size distribution 
and polydispersity index (PDI) of the reconstituted emulsions 
were measured at 25°C using Zetasizer Nano ZS90 (Malvern 
Instruments, Worcestershire, UK).
supersaturation assay
A solvent-shift method was employed to generate FNB 
supersaturation.24 The apparent drug concentration–time 
profile and the duration of the supersaturated state were 
determined using a USP II paddle method with a ZRS-8G 
dissolution tester (TDTF, Tianjing, China). A total medium 
volume of 200 mL with or without 0.05% (w/w) predis-
solved polymer was maintained at 37°C±0.5°C and the 
stirring speed was fixed at 100 rpm. The polymers used to 
stabilize the supersaturation were HPMC E3, HPMC E5, 
HPMC E15, PVP K30, PVP K90, PVP VA 64, and Soluplus. 
After adding 200 μL of FNB stock solution (100 mg/mL) 
in dimethylsulfoxide to the test medium, 2 mL of samples 
were withdrawn without volume replacement at 10, 30, 
60, 90, and 120 min and filtered through a 0.22 μm filter. 
All filters were prerinsed with 5 mL of a saturated solu-
tion of FNB in order to prevent adsorption onto the filter. 
The resulting filtrate was diluted appropriately in absolute 
ethanol and assayed by high-performance liquid chroma-
tography (HPLC LC-20AT; Shimadzu, Kyoto, Japan) at a 
wavelength of 286 nm. The area under the concentration–
time curve in supersaturated state (AUC
ss
) was computed 
according to the linear trapezoidal rule. Each dissolution 
test was performed in triplicate.
In vitro dissolution test under 
supersaturation condition for the 
sseDDs
The apparent drug concentration–time profiles of SSEDDS 
formulations were determined using a USP II paddle method 
(100 rpm, 37°C±0.5°C, 200 mL dissolution medium) with a 
ZRS-8G dissolution tester. The powdered Soluplus was mixed 
with solid self-emulsifying matrix at various polymer/drug 
ratios, ranging from 1/0.2 to 1/10 (w/w). The mixed samples 
containing equivalent amounts of FNB (100 mg) were added 
to each vessel. Two milliliters of aliquot samples were taken 
at predetermined time intervals (10, 30, 60, 90, and 120 min). 
The samples were filtered through a 0.22 μm polytetrafluo-
roethylene syringe filter, and the first 1 mL of filtrate was 
discarded. Then 0.5 mL of filtrate was immediately diluted 
in 10 mL of absolute ethanol to prevent the precipitation, and 
the concentration of FNB in samples was measured by HPLC. 
Each dissolution test was performed in triplicate.
solubility study
The solubility of FNB in deionized water containing various 
Soluplus concentrations (ranging from 0.00% to 0.50%) 
was measured to evaluate the mechanism of precipitation 
inhibition. Briefly, an excess amount of FNB was added to 
each capped vial containing 2 mL of Soluplus solution and 
mixed by vortexing. Then the mixture was kept at 37°C for 
72 h in a shaking water bath to facilitate the equilibrium. 
The equilibrated sample was centrifuged at 10,000 rpm for 
5 min to remove the undissolved drug. The supernatant was 
taken and diluted with methanol for quantification of FNB 
by HPLC system (Daojing, Japan) at 286 nm.
cytotoxicity on caco-2 cells
Human colorectal carcinoma Caco-2 cell line was obtained 
from American Type Culture Collection. The cells were 
cultured in DMEM supplemented with 10% fetal bovine 
serum, 1% l-glutamine, 1% nonessential amino acids, and 
100 U/mL of penicillin–streptomycin. The culture was 
maintained in a humidified incubator containing 5% CO
2
 at 
37°C. The growth medium was changed every 2 days prior 
to experimental use.
The cytotoxicity of liquid SEDDS formulation, mesopo-
rous silica SBA-15, and Soluplus was evaluated in Caco-2 
cells following the standard MTT viability assay. Cells were 
seeded in 96-well plates at a density of 5×103 cells/well and 
incubated for 48 h in 5% CO
2
 at 37°C till adherent growth. 
Subsequently, the medium was replaced with 200 μL of fresh 
medium containing different concentrations of test samples. 
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After incubation with the samples for 48 h, the medium was 
replaced with 180 μL of fresh medium and 20 μL of MTT 
(5 mg/mL). After another 4 h of incubation at 37°C, the 
medium was rejected and 150 μL of dimethylsulfoxide was 
added in each cell to dissolve the purple formazan crystals. 
Finally, the optical density value of each well was measured 
at 490 nm by an ELX 800 micro-plate reader. Cells treated 
with pure medium were used as the blank control. The cell 
viability for each test group vs blank control group was 
calculated based on six independent wells.
In vivo pharmacokinetic study
The in vivo pharmacokinetic study of SSEDDS (solid self-
emulsifying matrix) and optimized super-SSEDDS was 
conducted in beagle dogs. All the experimental procedures 
were approved by the Institutional Animal Care and Use 
Committee of Sun Yat-sen University in accordance with the 
National Institute of Health and Nutrition Guidelines for the 
care and use of laboratory animals. The study was conducted 
in six healthy beagle dogs (10–12 kg) in a nonrandomized 
cross-over manner, with a washout period of 2 weeks between 
each treatment. The animals were fasted for 12 h prior to the 
experiment, but allowed free access to water. Hard capsules 
containing the test samples equivalent to a dose of 100 mg 
FNB were administered orally, together with 20 mL of 
water. Water and food were returned at 2 and 4 h postdosing, 
respectively. Blood samples (5 mL) were withdrawn from the 
cephalic vein of the hind leg into heparinized tubes before 
administration and at 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 6, 8, and 
24 h postdosing. The plasma was harvested immediately by 
centrifugation of the blood samples at 5,000 rpm for 10 min 
and then kept frozen at -20°C until further analysis was 
conducted by the validated HPLC method.
Quantitative analysis of FNB in plasma
A Daojin series HPLC system (LC-20AT pump, DGU-20A
5R
 
system controller, and SPD-20A ultraviolet–visible detector; 
Daojin, Japan) and Phenomenex C18 column (4.6×250 mm, 
5 μm) with guard column were used. The mobile phase was 
composed of acetonitrile and 0.1% acetic acid (65:35, v/v) 
with a flow rate of 1.0 mL/min, and the run time was 30 min. 
The column working temperature was set to 40°C and the 
ultraviolet detection was performed at 286 nm. Indomethacin 
was used as the internal standard.
The samples for HPLC analysis were prepared by liquid–
liquid extraction. Briefly, 50 μL of methanol solution of 
the internal standard (50 μg/mL) was added to 500 μL of 
plasma, followed by 200 μL of HCl solution (1 mol/L). 
After vortex-mixing for 1 min, 4 mL of diethyl ether was 
added and the mixture was vortexed for another 5 min. After 
centrifuging at 8,000 rpm for 5 min, the organic layer was 
transferred to a microtube and evaporated under a stream of 
nitrogen at 40°C. Subsequently, the organic layer residue 
was reconstituted in 200 μL of mobile phase and vortexed 
for 5 min. Finally, the resulting mixture was centrifuged at 
15,000 rpm for 5 min. Then 50 μL of the supernatant was 
injected into HPLC for analysis.
Pharmacokinetic analysis and statistical 
analysis
The pharmacokinetic parameters were obtained by non-
compartmental analysis using WinNonlin V. 3.3 software 
(Pharsight, Sunnyvale, CA, USA). The maximum plasma con-
centration (C
max
) and the time to reach C
max
 (T
max
) were directly 
obtained from the plasma concentration–time curve. The 
AUC was estimated according to the linear trapezoidal rule.
All the data were expressed as the mean ± SD. The statis-
tical analysis of the mean pharmacokinetic parameters was 
performed using the Student’s t-test following normality and 
equal variance tests (SPSS 13.0). Also, the difference was 
considered to be statistically significant if the probability 
value was ,0.05 (P,0.05).
Results and discussion
Preparation of sseDDs matrix
Lipid SEDDS formulations could be transformed into solid 
dosage forms by using suitable absorbents. However, the 
reduced drug loading capacity in the final products is the main 
disadvantage of this formulation technique. The dilution of 
the liquid SEDDS during mixing with the solid absorbents 
and further dilution by addition of excipients to obtain dif-
ferent solid dosage forms is mainly responsible for reduced 
drug loading capacity.25 Therefore, the ideal solid absorbents 
which possess the ability to hold considerable amount of 
liquid formulation are essential in the development of a 
desirable SSEDDS.
In our previous study,13 a novel SSEDDS matrix of FNB 
was originally designed by using well-ordered 2-D hexagonal 
mesoporous silica SBA-15 as the inert solid absorbent. In this 
study, the absorption capacity of Aerosil 200, a colloidal 
silica, which has been adopted as one of the most com-
monly used solid carriers in previous studies,8,26–28 was also 
measured. When the ratio of Aerosil 200 to liquid SEDDS 
increased from 1:1 to 1:2 (w/w), the powdered solid samples 
were changed to sticky aggregates. However, the powder 
properties of the matrix were still obtained at a higher ratio 
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of 1:3 (SBA-15:liquid SEDDS), which confirmed the ability 
of SBA-15 to hold a larger amount of liquid SEDDS than 
conventional silica Aerosil 200. These results were consis-
tent with the nitrogen adsorption–desorption measurements. 
As shown in Figure 1A, SBA-15 exhibited typical type-IV 
isotherms containing H1-type hysteresis, suggesting the 
highly regular mesoporous structure of SBA-15. Whereas, 
the nitrogen adsorption–desorption isotherms of Aerosil 
200 were quite different (type-III) from those of SBA-15, 
suggesting the nonporous or macroporous solid character-
istics. The mean surface area, pore volume, and pore size of 
SBA-15 were calculated as 595.01 m2/g, 1.02 cm3/g, and 9.19 
nm, respectively. In contrast, the Brunauer-Emmett-Teller 
surface area of Aerosil 200 was only 155.93 m2/g, and no 
peak was recorded in the range of 2–50 nm (Figure 1B) for 
corresponding pore size distribution. These results suggested 
that the porous structure of SBA-15 played an important 
role in the solidification process. The mesoporous structure 
of SBA-15 was clearly observed by transmission electron 
microscopy; the straight lattice fringes at the parallel orien-
tation (Figure 2A) and the well-ordered hexagonal arrays at 
the vertical orientation (the insert in Figure 2A) confirmed 
the existence of hexagonal arrays of mesochannels.
The solid self-emulsifying matrix was prepared by adopt-
ing a fixed ratio (1:3, w/w) of SBA-15 to liquid SEDDS. 
As shown in Figure 2B, the obtained product appeared as 
white powder. The powder was further investigated for 
surface morphology using scanning electron microscopy. 
The crystals of FNB were found to be irregular with a 
smooth surface (Figure 2C), while the SSEDDS appeared 
as rough-surfaced particles (Figure 2D). No crystals of 
FNB were observed in the SSEDDS matrix, indicating that 
the liquid SEDDS was completely absorbed by mesoporous 
silica SBA-15. Additionally, the X-ray diffraction results 
showed that the diffraction peaks representing FNB crystal 
completely disappeared in the SSEDDS matrix, confirming 
that FNB in the matrix was in an amorphous or molecular 
state (Figure 3).
effect of various precipitation inhibitors 
on supersaturation assay
In developing an effective supersaturated formulation, it is 
essential to use a precipitation inhibitor to maintain the drug 
in supersaturated state in aqueous medium. In this study, 
several pharmaceutical polymers such as HPMC E3, HPMC 
E5, HPMC E15, PVP K30, PVP K90, PVP VA64, and 
Soluplus were screened as potential candidates for precipi-
tation inhibitors. The selection of polymers was motivated 
by their performance as precipitation inhibitors in several 
previous reports.16,29 In order to evaluate the apparent FNB 
concentration–time profile and duration of the supersatu-
rated state, in vitro dissolution test was conducted under a 
non-sink condition. The total volume of the medium chosen 
here was 200 mL, based on physiologic consideration of the 
total volume of the residual stomach fluid. Also, a solvent-
shift method was used to generate FNB supersaturation. 
As shown in Figure 4A, Soluplus significantly inhibited the 
precipitation of FNB, showing a consistently higher appar-
ent FNB concentration–time profile throughout the whole 
period of 2 h. In the case of other polymers including HPMC 
E3, HPMC E5, HPMC E15, PVP K30, PVP K90, and PVP 
VA64, the concentration of FNB decreased rapidly due to 
precipitation. To evaluate the supersaturation effect more 
specifically, the AUC
ss
 was calculated according to the linear 
trapezoidal rule. As shown in Figure 4B, the supersaturation 
capability of the precipitation inhibitors was in the sequence: 
Soluplus .. HPMC E5. HPMC E3–HPMC E15. PVP 
VA64. PVP K30–PVP K90. The AUC
ss
 of the Soluplus 
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Figure 1 (A) Nitrogen adsorption ()-desorption () isotherms of sBa-15 and aerosil 200. (B) Pore size distribution of sBa-15 and aerosil 200.
Abbreviations: sBa-15, santa Barbara amorphous-15; sTP, standard temperature and pressure.
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group was 10.01 times higher than that of HPMC E5. These 
results clearly demonstrated that a small amount of Soluplus 
could retard FNB precipitation effectively and sustain a 
higher apparent concentration over ~120 min.
effect of soluplus amount on drug 
dissolution from sseDDs
In order to investigate the influence of Soluplus amount 
upon the supersaturated state as a function of time, a series 
of solid self-emulsifying formulations containing the precipi-
tation inhibitor at various polymer/drug ratios were evalu-
ated. The apparent FNB concentration in aqueous medium 
increased with increase in Soluplus proportion (Figure 5). 
When the Soluplus:FNB ratio reached 1:1, the precipitation 
inhibition effect was amplified. However, a further increase 
in Soluplus:FNB ratio from 1:1 to 10:1 had a little effect, 
yielding similar apparent FNB concentration–time profiles. 
Based on these results, the optimized formula for FNB and 
Soluplus at a ratio of 1:1 was finally established as the super-
SSEDDS of FNB.
To evaluate the reconstitution property of the solid self-
emulsifying formulations, the appearance, droplet size, and 
PDI of the reconstituted emulsions were evaluated. As shown 
in Figure 6, clear and slightly bluish emulsions with obvious 
Tyndall effect were observed. The mean droplet size and 
PDI of SSEDDS were recorded as 125.23±1.50 nm and 
??????
?????? ??? ??????? ?????? ????? ???????
???????? ?????????? ?????? ????????? ?????????????????? ????????? ??????????? ?????????????????????
? ?
? ?
Figure 2 Images of different samples.
Notes: (A) Transmission electron microscopic images of sBa-15 at parallel orientation with vertical orientation shown in the inset. (B) The photograph of sseDDs matrix. 
(C) scanning electron microscopic images of FNB and (D) sseDDs matrix. 
Abbreviations: FNB, fenofibrate; SBA-15, Santa Barbara Amorphous-15; SSEDDS, solid self-emulsifying drug delivery systems.
?? ?? ?? ?? ??
??????
??????
???
????????????????
Figure 3 Wide-angle X-ray diffraction patterns of crystal FNB, sBa-15, sseDDs, 
and physical mixture.
Abbreviations: FNB, fenofibrate; SBA-15, Santa Barbara Amorphous-15; SSEDDS, 
solid self-emulsifying drug delivery systems.
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0.19±0.01, respectively, which suggest the well-retained 
self-emulsifying ability in the solid matrix. The mean droplet 
size of the Soluplus-incorporated formulation was slightly 
larger than that of conventional SSEDDS due to the absorp-
tion of Soluplus on the particle surfaces and the enhanced 
steric stabilization generated by the strongly hydrated 
polymer chain.
Mechanism of precipitation inhibition
Drug precipitation is normally separated into two stages: 
nucleation and crystal growth. At the first stage, dissolved 
drug molecules in solution start to aggregate into small 
clusters. The clusters continue to grow, which eventually 
leads to the formation of nuclei that can act as centers of 
crystallization and move to the second stage, crystal growth.30 
Crystal growth is the stage where growth units gather into 
the surface of the existing nuclei and ultimately arrange into 
the crystal structure.31,32
Drug molecules tend to precipitate after supersaturation 
induction.22 The concept of generation and maintenance of 
a metastable supersaturated state is commonly described 
by the “Spring and Parachute” theory.33 A higher energy 
form of drug molecule in supersaturated solution is usually 
?
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Figure 4 The results of supersaturation assay.
Notes: (A) Apparent FNB concentration–time profiles obtained from in vitro dissolution test under a non-sink condition. (B) The aUcss calculated according to the linear 
trapezoidal rule (mean ± sD, n=3).
Abbreviations: aUcss, the area under the concentration–time curve in supersaturated state; FNB, fenofibrate; HPMC, hydroxypropyl methyl cellulose; PVP, 
polyvinylpyrrolidone.
?????
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??? ??? ???????????????????
???
??
? ? ??
Figure 5 The aUcss values of super-sseDDs containing various polymer/drug 
ratios under a non-sink condition dissolution test (mean ± sD, n=3).
Abbreviations: aUcss, the area under the concentration–time curve in 
supersaturated state; FNB, fenofibrate; SSEDDS, solid self-emulsifying drug delivery 
systems.
?
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????????????????????
?????????????????
?????????????????
???????
????????????
? ?
Figure 6 characterization of the reconstituted emulsion.
Notes: (A) The droplet size and PDI of the reconstituted emulsions from different 
formulations (mean ± sD, n=3). The appearance of reconstituted emulsion of 
sseDDs (B) and super-sseDDs (C) in the presence of a red laser light.
Abbreviations: PDI, polydispersity index; sseDDs, solid self-emulsifying drug 
delivery systems.
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thermodynamically unstable (a spring). The degree of 
supersaturation (S = C/C
s
, also known as supersaturation 
ratio, where C is the total drug concentration and C
s
 is the 
saturation concentration of the drug in the solvent) is the 
driving force for the precipitation. The higher the initial 
degree of supersaturation, the more rapid precipitation will 
happen.34 Recently, a series of pharmaceutical excipients 
have been successfully explored as precipitation inhibitors 
(“parachutes”) for temporary inhibition of drug precipita-
tion.35 Inhibition of drug precipitation can be achieved ther-
modynamically by reducing the degree of supersaturation, or 
kinetically by inhibiting or retarding the drug precipitation 
in supersaturated systems.29
In supersaturated solution, when the concentration of 
surfactants exceeds their critical micelle concentration, an 
improvement in drug solubility will inhibit the precipitation 
by reducing the degree of supersaturation. Soluplus has the 
potential to act as a surfactant due to hydrophilic polyeth-
ylene glycol and hydrophobic polycaprolactam groups. The 
saturation solubility of FNB in a series of Soluplus solu-
tions was measured. As shown in Table 1, the equilibrium 
solubility of FNB in deionized water was recorded as only 
0.22±0.01 μg/mL. As the concentration of Soluplus increased 
from 0.1 to 5.0 mg/mL, the saturation solubility of FNB 
gradually increased, indicating that FNB was incorporated 
in the hydrophobic regions of the micelles. In this study, 
the final concentration of Soluplus for super-SSEDDS in 
the dissolution medium was 0.5 mg/mL, which was above 
its critical micelle concentration (7.6 μg/mL).36 Therefore, 
the increased saturation solubility could reduce the degree 
of supersaturation, which ultimately results in retarded 
precipitation.
It was reported that the nucleation activation energy 
was increased by hydrogen bonding between polymers and 
drug molecules, leading to delayed nucleation and crystal 
growth.37,38 In this study, FNB has two carbonyl groups 
(hydrogen-bond acceptor) that can form hydrogen bonds. 
Since Soluplus has two hydroxyl groups (hydrogen-bond 
donor) and HPMC has only one hydroxyl group per mono-
mer unit, Soluplus–FNB association is expected to be 
stronger than HPMC–FNB, leading to effective precipitate 
inhibition. In contrast, both PVP and PVP VA64 are rich in 
carbonyl groups (hydrogen-bond acceptor) and have lower 
tendency to form hydrogen bonds with FNB, thus resulting 
in poor inhibition ability. Similar observations have also 
been reported previously, suggesting that polymers rich 
in hydrogen-bond donors are more suitable for drugs with 
hydrogen-bond acceptors in order to construct an effective 
supersaturated drug delivery system.16,20
Based on the results obtained, it may be concluded that 
inhibition of FNB precipitation could be achieved both ther-
modynamically and kinetically by Soluplus. Thermodynami-
cally, Soluplus increased the apparent saturation solubility 
and decreased the extent of supersaturation. Kinetically, it 
might also interact with FNB by hydrogen bonding. This 
combinational mechanism resulted in the enhanced Spring 
and Parachute effect, consequently leading to a better inhibi-
tion effect (Figure 7).
In vitro cytotoxicity of seDDs, sBa-15, 
and soluplus
The biosafety of the excipients must be considered before 
their application. Caco-2 cells have been widely used as a 
cellular model to simulate the human intestinal epithelium.39 
Herein, liquid SEDDS formulation, mesoporous silica 
SBA-15, and Soluplus were incubated with Caco-2 for 
48 h at a broad concentration range of 10–400 μg/mL and 
their cytotoxicity was evaluated by MTT assay. As shown 
in Figure 8, all the samples showed negligible cytotoxicity 
as the cell viabilities of all samples remained above 90%, 
demonstrating that the excipients used in this study are bio-
compatible for oral drug delivery.
Table 1 solubility of FNB in a series of soluplus solutions at 
25°c (mean ± sD, n=3)
Concentration of Soluplus (mg/mL) Solubility (μg/mL)
0 0.22±0.01
0.1 0.29±0.18
0.3 0.41±0.20
0.5 0.45±0.12
1.0 0.79±0.07
3.0 2.97±0.84
5.0 3.15±0.97
Abbreviation: FNB, fenofibrate.
?? ?
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Figure 7 schematic showing the mechanism of precipitation inhibition.
Abbreviation: FNB, fenofibrate.
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In vivo pharmacokinetic study
The formulations of super-SSEDDS and SSEDDS were 
orally administered to six healthy beagle dogs, with the 
dose of FNB being 100 mg. FNB is hydrolyzed into the 
main active metabolite fenofibric acid by plasma and tissue 
esterases, and the profiles of mean plasma concentrations of 
fenofibric acid vs time are presented in Figure 9. The drug 
plasma concentrations of super-SSEDDS were higher than 
those of solid self-emulsifying matrix without precipitation 
inhibitor at all the indicated time points. The pharmacokinetic 
parameters were calculated and are summarized in Table 2. 
Both SSEDDS formulations showed rapid absorption with 
a short T
max
 around 2 h, and the super-SSEDDS showed a 
higher AUC value of 45.05 μg h/mL as compared to that of 
the SSEDDS formulation (32.74 μg h/mL).
It is reported that SEDDS can offer remarkable 
improvement in the solubility and bioavailability of poorly 
water-soluble drugs.40 The spontaneous formation of oil-in-
water emulsion upon drug release process presents the drug 
in a dissolved form with nano-scale droplets. These small 
droplets provide a huge interfacial area favorable for drug 
absorption.41 The self-emulsifying ability of the obtained 
SSEDDS was well retained, and a uniform O/W microemul-
sion was formed when introduced to the aqueous media 
under mild agitation. Additionally, the super-SSEDDS could 
further improve the oral absorption of FNB, showing even 
40% greater relative bioavailability than that of SSEDDS. 
These results were in good agreement with the in vitro results 
described above, implying that the supersaturable formula-
tion was able to induce a higher free drug concentration in 
the GI tract over a longer period of time. Moreover, Soluplus 
has been reported to be an effective absorption enhancer 
for inhibiting the biologic activity of P-glycoprotein.42,43 
Therefore, the P-glycoprotein inhibition afforded by Soluplus 
cannot be excluded and may account for the increased oral 
absorption.
Both the in vitro dissolution test under supersaturation 
condition and the in vivo pharmacokinetic performance 
clearly indicate that the super-SSEDDS containing Soluplus 
is remarkably effective in inhibiting FNB precipitation and 
improving the rate and extent of drug absorption.
Conclusion
In summary, a novel super-SSEDDS formulation was 
successfully designed by incorporation of amphiphilic 
polymer Soluplus as a precipitation inhibitor. An optimized 
SSEDDS containing FNB was developed by using mesopo-
rous silica as the insert reservoir. The in vitro dissolution 
test under supersaturation condition clearly demonstrated 
that Soluplus effectively suppressed the drug precipita-
tion and maintained a metastable supersaturated state. The 
in vivo pharmacokinetic study in beagle dogs indicated 
that the super-SSEDDS significantly improved the oral 
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Figure 8 The viabilities of caco-2 cells treated with varying concentrations of 
samples for 48 h at 37°c (mean ± sD, n=6).
Abbreviations: sBa-15, santa Barbara amorphous-15; seDDs, self-emulsifying 
drug delivery systems.
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Figure 9 Plasma drug concentration–time profiles after oral administration of 
sseDDs and super-sseDDs matrix (mean ± sD, n=6).
Abbreviation: sseDDs, solid self-emulsifying drug delivery systems.
Table 2 PK parameters of FNB following oral administration of 
single 100 mg dose of sseDDs and super-sseDDs (mean ± sD, 
n=6)
PK parameter SSEDDS super-SSEDDS
Cmax (μg/ml) 4.23±1.39 4.50±2.07
Tmax (h) 1.50±0.35 2.10±1.14
t1/2 (h) 13.80±6.14 14.39±6.43
aUc(0→∞) (μg h/ml) 32.74±8.11 45.05±14.50*
Note: *P,0.05.
Abbreviations: aUc(0→∞), area under the plasma concentration–time curve; Cmax, 
peak plasma concentration; FNB, fenofibrate; SSEDDS, solid self-emulsifying drug 
delivery systems; PK, pharmacokinetic; t1/2, elimination half-time; Tmax, time to reach 
peak plasma concentration.
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absorption of FNB, providing about 40% greater relative 
bioavailability when compared to SSEDDS. In a nutshell, the 
super-SSEDDS formulation containing Soluplus provides an 
effective approach to improve the oral absorption of poorly 
water-soluble drugs.
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